{"title":"Early Awake Prone Position Combined with High-Flow Nasal Oxygen Therapy in Severe COVID-19: A Case Series.","authors":"Y Chengfen, Z Yongle, L Jianguo, X Lei","doi":"10.1007/s44231-022-00026-z","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Awake prone positioning has been used for non-intubated patients with COVID-19-related acute hypoxaemic respiratory failure, but the results are contradictory. We aimed to highlight the role of awake prone positioning combined with high-flow nasal oxygen therapy in severe COVID-19 patients infected with the Delta variant of SARS-CoV-2.</p><p><strong>Methods: </strong>From June 12 to December 7, 2021, we successfully performed prone position(PP) combined with high-flow nasal oxygen(HFNO) therapy on two patients infected with the delta variant of SARS-CoV-2. HFNO was prescribed to reach SpO<sub>2</sub> ≥ 92%. PP was proposed to patients with PaO<sub>2</sub>/FiO<sub>2</sub>(P/F) < 150 mmHg. Arterial blood gas (ABG) and hemodynamic were monitored before and after PP sessions. The target time of PP was more than 12 h per day and could be appropriately shortened according to the patient's tolerance. Relevant clinical data, HFNO parameters, PICCO parameters, P/F ratio and PP duration were obtained from medical records.</p><p><strong>Results: </strong>A total of 23 PP sessions and 6 PP sessions combined with HFNO were performed in case 1 and case 2, respectively. Compared with values before PP, GEDI, ELWI and Qs/Qt decreased significantly (GEDI: 869.50 ± 60.50 ml/m<sup>2</sup> vs. 756.86 ± 88.25 ml/m<sup>2</sup>; ELWI: 13.64 ± 2.82 ml/kg vs. 12.43 ± 2.50 ml/kg; Qs/Qt: 15.32 ± 6.52% vs. 12.24 ± 5.39%; all p < 0.05), Meanwhile, the oxygenation improved significantly (P/F: 184.50 ± 51.92 mmHg vs. 234.21 ± 88.84 mmHg, p < 0.05), The chest CT revealed the lung infiltrates improved significantly after PP. Both cases were discharged to a dedicated COVID-19 ward without requiring intubation.</p><p><strong>Conclusions: </strong>Combining PP with HFNO could be a useful treatment strategy for avoiding intubation in severe COVID-19 patients infected with the Delta variant of SARS-CoV-2 to improve pulmonary vascular involvement, improve oxygenation and avoid intubation, but further studies are needed to validate our approach.</p>","PeriodicalId":73403,"journal":{"name":"Intensive care research","volume":"3 1","pages":"83-86"},"PeriodicalIF":0.0000,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9778461/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Intensive care research","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1007/s44231-022-00026-z","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
Abstract
Background: Awake prone positioning has been used for non-intubated patients with COVID-19-related acute hypoxaemic respiratory failure, but the results are contradictory. We aimed to highlight the role of awake prone positioning combined with high-flow nasal oxygen therapy in severe COVID-19 patients infected with the Delta variant of SARS-CoV-2.
Methods: From June 12 to December 7, 2021, we successfully performed prone position(PP) combined with high-flow nasal oxygen(HFNO) therapy on two patients infected with the delta variant of SARS-CoV-2. HFNO was prescribed to reach SpO2 ≥ 92%. PP was proposed to patients with PaO2/FiO2(P/F) < 150 mmHg. Arterial blood gas (ABG) and hemodynamic were monitored before and after PP sessions. The target time of PP was more than 12 h per day and could be appropriately shortened according to the patient's tolerance. Relevant clinical data, HFNO parameters, PICCO parameters, P/F ratio and PP duration were obtained from medical records.
Results: A total of 23 PP sessions and 6 PP sessions combined with HFNO were performed in case 1 and case 2, respectively. Compared with values before PP, GEDI, ELWI and Qs/Qt decreased significantly (GEDI: 869.50 ± 60.50 ml/m2 vs. 756.86 ± 88.25 ml/m2; ELWI: 13.64 ± 2.82 ml/kg vs. 12.43 ± 2.50 ml/kg; Qs/Qt: 15.32 ± 6.52% vs. 12.24 ± 5.39%; all p < 0.05), Meanwhile, the oxygenation improved significantly (P/F: 184.50 ± 51.92 mmHg vs. 234.21 ± 88.84 mmHg, p < 0.05), The chest CT revealed the lung infiltrates improved significantly after PP. Both cases were discharged to a dedicated COVID-19 ward without requiring intubation.
Conclusions: Combining PP with HFNO could be a useful treatment strategy for avoiding intubation in severe COVID-19 patients infected with the Delta variant of SARS-CoV-2 to improve pulmonary vascular involvement, improve oxygenation and avoid intubation, but further studies are needed to validate our approach.
背景:清醒俯卧位已被用于非插管的covid -19相关急性低氧性呼吸衰竭患者,但结果是矛盾的。我们的目的是强调清醒俯卧位联合高流量鼻氧治疗在SARS-CoV-2变异感染的重症COVID-19患者中的作用。方法:于2021年6月12日至12月7日,对2例SARS-CoV-2型δ型变异患者成功实施俯卧位联合高流量鼻氧治疗。规定HFNO达到SpO2≥92%。对PaO2/FiO2(P/F)患者进行PP治疗。结果:病例1和病例2分别进行了23次PP治疗和6次PP联合HFNO治疗。与PP治疗前相比,GEDI、ELWI、Qs/Qt均显著降低(GEDI: 869.50±60.50 ml/m2 vs. 756.86±88.25 ml/m2;ELWI: 13.64±2.82 ml/kg vs. 12.43±2.50 ml/kg;Qs/Qt: 15.32±6.52% vs. 12.24±5.39%;结论:PP联合HFNO可能是一种有效的治疗策略,可以改善肺血管受累,改善氧合,避免插管,但需要进一步的研究来验证我们的方法。